Truist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)

Truist Financial analyst Joon Lee reiterated a Buy rating on Taysha Gene Therapies (TSHA – Research Report) today. The company’s shares closed yesterday at $2.57.

Lee covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Wave Life Sciences, and Catalyst Pharma. According to TipRanks, Lee has an average return of 23.9% and a 49.17% success rate on recommended stocks.

Taysha Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $7.17, a 178.99% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $7.00 price target.

The company has a one-year high of $3.89 and a one-year low of $0.50. Currently, Taysha Gene Therapies has an average volume of 2.89M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies (TSHA) Company Description:

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.